Immuno-oncology combinations: raising the tail of the survival curve
Open Access
- 1 January 2016
- journal article
- Published by China Anti-cancer Association in Cancer Biology & Medicine
- Vol. 13 (2), 171-193
- https://doi.org/10.20892/j.issn.2095-3941.2016.0015
Abstract
There have been exponential gains in immuno-oncology in recent times through the development of immune checkpointinhibitors. Already approved by the U.S. Food and Drug Administration for advanced melanoma and non-small cell lung cancer,immune checkpoint inhibitors also appear to have significant antitumor activity in multiple other tumor types. An excitingcomponent of immunotherapy is the durability of antitumor responses observed, with some patients achieving disease control formany years. Nevertheless, not all patients benefit, and efforts should thus now focus on improving the efficacy of immunotherapythrough the use of combination approaches and predictive biomarkers of response and resistance. There are multiple potentialrational combinations using an immunotherapy backbone, including existing treatments such as radiotherapy, chemotherapy ormolecularly targeted agents, as well as other immunotherapeutics. The aim of such antitumor strategies will be to raise the tail onthe survival curve by increasing the number of long term survivors, while managing any additive or synergistic toxicities that mayarise with immunotherapy combinations. Rational trial designs based on a clear understanding of tumor biology and drugpharmacology remain paramount. This article reviews the biology underpinning immuno-oncology, discusses existing and novelimmunotherapeutic combinations currently in development, the challenges of predictive biomarkers of response and resistanceand the impact of immuno-oncology on early phase clinical trial design.Keywords
This publication has 100 references indexed in Scilit:
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in CancerThe New England Journal of Medicine, 2012
- Immunologic Correlates of the Abscopal Effect in a Patient with MelanomaThe New England Journal of Medicine, 2012
- Expression of tumour-specific antigens underlies cancer immunoeditingNature, 2012
- Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of IdoNature Medicine, 2011
- MDSC as a mechanism of tumor escape from sunitinib mediated anti-angiogenic therapyInternational Immunopharmacology, 2011
- Hallmarks of Cancer: The Next GenerationCell, 2011
- Immune parameters affecting the efficacy of chemotherapeutic regimensNature Reviews Clinical Oncology, 2011
- Minimal information about T cell assays: the process of reaching the community of T cell immunologists in cancer and beyondCancer Immunology, Immunotherapy, 2010
- Improved Survival with Ipilimumab in Patients with Metastatic MelanomaThe New England Journal of Medicine, 2010
- Sipuleucel-T Immunotherapy for Castration-Resistant Prostate CancerThe New England Journal of Medicine, 2010